JASON R BEGUE
- Type
- Physician · Allopathic & Osteopathic Physicians / Emergency Medicine
- Where
- GREENVILLE, MS
- NPI
- 1336120682
- Received
- $630,039 in 14 records, 2020 to 2025 ($126 general, $629,912 research)
- As principal investigator
- $1,020,154 of research payments to others in 11 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 2 | $30 |
| 2023 | Research payment | 2 | $16,791 |
| 2022 | General payment | 2 | $33 |
| 2022 | Research payment | 2 | $591,281 |
| 2021 | General payment | 4 | $62 |
| 2021 | Research payment | 1 | $8,540 |
| 2020 | Research payment | 1 | $13,300 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 6 | $629,912 | 2020–2023 |
| ABBVIE INC. | 6 | $98 | 2021–2023 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 | 2021 |
| Alexion Pharmaceuticals, Inc. | 1 | $13 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 6 | $629,912 |
| Food and Beverage | 8 | $126 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-10-11 | Eli Lilly and Company | $12,166 | Research payment | Cash or cash equivalent | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 | |
| 2023-09-20 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | TEFLARO Drug, ANTI-INFECTIVE | 2023 | |
| 2023-05-31 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | AVYCAZ Drug, ANTI-INFECTIVE | 2023 | |
| 2023-01-10 | Eli Lilly and Company | $4,625 | Research payment | In-kind items and services | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 | |
| 2022-11-29 | Eli Lilly and Company | $573,630 | Research payment | Cash or cash equivalent | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 | |
| 2022-09-06 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | AVYCAZ Drug, ANTI-INFECTIVE | 2022 | |
| 2022-07-09 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2022 | |
| 2022-04-08 | Eli Lilly and Company | $17,651 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 | |
| 2021-11-16 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-10-14 | Alexion Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | Andexxa Drug, Hematology | 2021 | |
| 2021-08-04 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2021 | |
| 2021-05-05 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | LOKELMA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-01-05 | Eli Lilly and Company | $8,540 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 IN PREVENT | 2021 | |
| 2020-11-09 | Eli Lilly and Company | $13,300 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 IN PREVENT | 2020 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-01-09 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $2,778 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2025-01-07 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $86,783 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2024-01-09 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $4,846 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
| 2024-01-02 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $233,829 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
| 2023-07-11 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $3,289 | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 |
| 2023-01-03 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $599,362 | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 |
| 2022-05-11 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $21,741 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 |
| 2022-03-11 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $12 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 |
| 2021-02-08 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $66,725 | A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 IN PREVENT | 2021 |
| 2021-01-27 | Eli Lilly and Company | MILLERS HEALTH SYSTEMS INC | $50 | A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 IN PREVENT | 2021 |
| 2020-08-04 | Eli Lilly and Company | CARE ACCESS RESEARCH LLC | $738 | A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 IN PREVENT | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Greenville, MS, county Washington County, MS, state Mississippi; placed by its city name.
| Measure | Place (city or town) Greenville, MS | County Washington County, MS | State Mississippi |
|---|---|---|---|
| Population B01003 | 28,166 | 42,765 | 2,946,779 |
| Population, 2020 census P1 | 29,670 | 44,922 | 2,961,279 |
| Median age B01002 | 37.8 | 38.0 | 38.6 |
| Under 18 B01001 | 25.7% | 25.6% | 23.3% |
| 65 and over B01001 | 17.4% | 17.8% | 17.2% |
| Households B11001 | 11,249 | 17,113 | 1,145,431 |
| Foreign born B05002 | 0.7% | 0.7% | 2.4% |
| Median household income B19013 | $40,083 | $42,165 | $56,447 |
| Median family income B19113 | $49,175 | $53,425 | $73,163 |
| Per capita income B19301 | $23,829 | $25,149 | $31,549 |
| Poverty rate B17001 | 28.0% | 26.4% | 18.9% |
| Unemployment rate B23025 | 6.7% | 6.3% | 5.8% |
| Civilian labor force B23025 | 11,197 | 17,417 | 1,332,121 |
| Mean commute (minutes) B08013 | 18.8 | 19.6 | 25.6 |
| Bachelor's degree or higher B15003 | 22.0% | 22.4% | 25.1% |
| Housing units B25001 | 13,918 | 20,867 | 1,341,114 |
| Owner-occupied B25003 | 53.9% | 60.2% | 70.0% |
| Renters B25003 | 46.1% | 39.8% | 30.0% |
| Median home value B25077 | $103,800 | $104,000 | $169,800 |
| Median gross rent B25064 | $872 | $833 | $954 |
| White, not Hispanic B03002 | 14.9% | 23.9% | 55.2% |
| Black B03002 | 82.4% | 71.4% | 36.3% |
| Hispanic or Latino B03002 | 0.3% | 1.6% | 3.7% |
| Asian B03002 | 1.2% | 0.8% | 1.0% |
| American Indian and Alaska Native B03002 | 0.1% | 0.0% | 0.4% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Greenville, MS.
Comments